← Back to Home

AGC’s Yokohama Site Takes On Three Cell Therapy Projects, Supporting Research on Post-Transplant Adenovirus Infection

Institute of Science Tokyo hopes to use third-party virus-specific T cells to tackle refractory adenovirus infection following hematopoietic cell transplantation. AGC Biologics will help develop processes and analytical methods, laying the manufacturing groundwork for the research to move toward clinical use, but this collaboration has not yet provided new evidence of efficacy.

By SURL BioNews

For patients who have undergone hematopoietic cell transplantation and whose immune function has not yet recovered, viral infections can pose a serious threat. Institute of Science Tokyo is studying virus-specific T cells to treat refractory adenovirus infection and has selected AGC Biologics’ Yokohama site in Japan to help develop the processes and analytical methods needed to move toward clinical use.

This research is one of three new collaborations recently announced by AGC. According to the company announcement and a GlobeNewswire press release republished by Ritzau, three developers have selected Yokohama’s cell therapy services for work covering process transfer and manufacturing for preclinical studies and clinical trials. Yokohama’s cell therapy services began in July 2025, and this announcement reflects progress in bringing in new projects and putting those services to use.

The Institute of Science Tokyo project uses “third-party virus-specific T cells”—immune cells from third-party donors that can recognize specific viruses—with the aim of advancing a treatment for adenovirus infection that responds poorly to existing treatments following hematopoietic cell transplantation. The research is supported by the Japan Agency for Medical Research and Development (AMED) under its research program on intractable diseases; the announcement did not provide patient numbers, viral clearance rates, or survival outcomes.

AGC’s work in this research focuses on how the cells are prepared and how analytical methods are established. For cell therapies to move from laboratory research to human use, preparation and quality assessment must be translated into reproducible procedures. This collaboration addresses that part of the development work; it does not establish that the therapy has proven effective or received marketing authorization.

Another new collaboration involves an international process transfer: a customer project originally handled by AGC’s Milan site in Italy will move to Yokohama for further development and manufacturing. The company has not disclosed the customer’s name, the therapeutic indication, or the transfer timeline. What can currently be confirmed is therefore a change in service location; the actual impact on trial progress or supply scale cannot yet be determined.

The three collaborations make the Yokohama site’s role more concrete: meeting the clinical translation needs of academic research on one side and supporting existing customers’ international development work on the other. However, publicly available information comes primarily from the same company announcement and its republications. Contract values, the full development stage of each project, and manufacturing scale have not been disclosed. Safety and efficacy, which matter most to patients, still require answers from subsequent clinical data.

References

  1. Contract Pharma
  2. AGC Biologics
  3. GlobeNewswire via Ritzau